About ADMA Biologics (ADMA)

ADMA Biologics Inc (ADMA), a biopharmaceutical company, engages in the development and commercialization of specialty plasma-based biologics for the treatment of immune deficiencies and infectious diseases. The company's lead product, BIVIGAM, is a plasma-derived intravenous immunoglobulin (IVIG) for the treatment of primary humoral immunodeficiency. ADMA is also developing three other products, including RI-002, a plasma-derived polyclonal antibody product for the treatment of respiratory syncytial virus; Asceniv, a polyclonal antibody product candidate for the treatment of primary humoral immunodeficiency; and Nabi-HB, a plasma-derived polyclonal antibody containing a high level of antibodies to hepatitis B surface antigen for the treatment of pediatric patients. The company sells its products through distributors and direct sales. ADMA Biologics Inc was founded in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics Inc (ADMA) has a market capitalization of $423.83 million. The company's PEG ratio, which measures the relationship between the price/earnings ratio and the company's projected earnings growth rate, is -3.06. A PEG ratio below 1 is generally considered to be undervalued. ADMA Biologics Inc operates in the biotechnology industry, which has a trailing twelve-month P/E ratio of 23.16. ADMA's P/E ratio stands at -2.16. The company's stock has a 52-week range of $1.87 to $5.42. ADMA Biologics Inc's stock is currently trading within its day range of $4.45 to $4.60. The trading volume for ADMA Biologics Inc's stock is 1,234,567 shares.